Immunoglobulins Intravenous (Human)

DRUG3 trials

Sponsors

CSL Behring

Conditions

AgammaglobulinemiaCommon Variable ImmunodeficiencyIgG Deficiency

Phase 3

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

CompletedNCT00168025

CSL BehringAgammaglobulinemia, Common Variable Immunodeficiency, IgG Deficiency

Start: 2004-09-30End: 2006-03-31Updated: 2012-06-06

Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

CompletedNCT00168012

CSL BehringAgammaglobulinemia, Common Variable Immunodeficiency, IgG Deficiency

Start: 2004-09-30End: 2005-09-30Target: 42Updated: 2011-02-11

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

CompletedNCT00322556

CSL BehringAgammaglobulinemia, Common Variable Immunodeficiency, IgG Deficiency

Start: 2005-11-30End: 2008-04-30Updated: 2012-10-26

Related Papers

Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.

2018-11-155 citations